Investing.com - Biomarin Pharma (NASDAQ:BMRN) reported on Wednesday second quarter earnings that beat analysts' forecasts and revenue that topped expectations.
Biomarin Pharma announced earnings per share of $0.07 on revenue of $501.7M. Analysts polled by Investing.com anticipated EPS of $-0.1093 on revenue of $447.6M.
Biomarin Pharma shares are down 14% from the beginning of the year, still down 36.83% from its 52 week high of $124.52 set on August 5, 2020. They are under-performing the Nasdaq 100 which is up 16.53% from the start of the year.
Biomarin Pharma follows other major Healthcare sector earnings this month
Biomarin Pharma's report follows an earnings beat by J&J on July 21, who reported EPS of $2.48 on revenue of $23.31B, compared to forecasts EPS of $2.29 on revenue of $22.49B.
UnitedHealth had beat expectations on July 15 with second quarter EPS of $4.7 on revenue of $71.32B, compared to forecast for EPS of $4.43 on revenue of $69.51B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar